1526-IMIQ

About this trial

Last updated 3 years ago

Study ID

1526-IMIQ

Status

Completed

Type

Interventional

Phase

Phase 4

Placebo

Accepting

18+ Years

All

Not accepting

Healthy Volunteers

Trial Timing

Ended 18 years ago

The purpose of this study is to compare the recurrence rate following total clearance of external genital warts (EGWs) when clearance has been obtained by imiquimod (3 applications per week for 4 weeks) followed by ablative therapy (laser or electrocautery therapy) with that from just ablative therapy treatment alone.

Inclusion Criteria

- Subjects with at least 1 visible genital or perianal wart

- Total wart area 1 to 40 square centimeters.

Exclusion Criteria

- Pregnant or lactating women

- Known other sexually transmitted disease

- Evidence of a clinically significant immunodeficiency

- Evidence of unstable cardiovascular, pulmonary, hematological, hepatic, renal, endocrine, collagen vascular, neurological or gastrointestinal abnormality or disease.

- Treatment within the 4 weeks prior to the Randomization Visit with any of the following systemic or topical treatments: interferons, interferon inducers, immunomodulators, immunosuppressive drugs, antiviral drugs (except for systemic acyclovir, valacyclovir and famciclovir), cytotoxic drugs, investigational drugs, or any drugs known to have major organ toxicity.

Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts